Roivant (ROIV) and Priovant Therapeutics reported positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, showing the strongest efficacy data in NIU observed to date.
Roivant Sciences' experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's.
No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.